Abstract
Radioactive iodine-131 (I-131) therapy has long been an effective treatment modality for benign thyroid diseases as well as for ablation of remnant thyroid tissue, adjuvant therapy, and control of metastatic disease in differentiated thyroid cancer. In order to maximize therapeutic efficacy and minimize potential toxicities, a structured preparation process is required following risk stratification based on current guidelines, after determining the treatment indication and the activity dose to be administered. In this review, a systematic approach will be presented addressing thyroid-stimulating hormone stimulation methods, iodine restriction, preparation principles in special patient populations, and safety strategies in patients for whom I-131 therapy has been indicated and the therapeutic dose has been planned.
Keywords:
Radioactive iodine therapy, I-131, differentiated thyroid cancer
References
1
Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid Cancer. Thyroid. 2025;35:841-985. Erratum in: Thyroid. 2025;35:1350.
2
Cooper DS, Doherty GM, Haugen BR, et al.; American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
3
Luster M, Clarke SE, Dietlein M, et al.; European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941-1959.
4
Lipp HP. Administration and pharmacokinetics of levothyroxine. 2021 Mar 12. In: Kahaly GJ, editor. 70 Years of Levothyroxine [Internet]. Cham (CH): Springer; 2021.
5
Kannan S, Mahadevan S, Sadacharan D, Thirumurthi K. Is 3-4 weeks required for TSH to rise post thyroidectomy? A prospective study and discussion of its implications on patient care. Indian J Endocrinol Metab. 2019;23:452-455.
6
Edmonds CJ, Hayes S, Kermode JC, Thompson BD. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol. 1977;50:799-807.
7
Bacher R, Hohberg M, Dietlein M, et al. Thyroid uptake and effective half-life of radioiodine in thyroid cancer patients at radioiodine therapy and follow-up whole-body scintigraphy either in hypothyroidism or under rhTSH. J Nucl Med. 2019;60:631-637.
8
Taïeb D, Sebag F, Cherenko M, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf). 2009;71:115-123.
9
Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010;20:173-179.
10
Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005;12:49-64.
11
Robbins RJ, Driedger A, Magner J; U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid. 2006;16:1121-1130.
12
Türkiye Endokrinoloji ve Metabolizma Derneği. Tiroid hastalıkları tanı ve tedavi kılavuzu 2025. Ankara: Türkiye Endokrinoloji ve Metabolizma Derneği; 2025. Available from: https://file.temd.org.tr/Uploads/publications/guides/documents/tiroid2025_11042025.pdf
13
Hocevar M, Auersperg M, Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. Eur J Surg Oncol. 1997;23:208-210.
14
Spencer CA. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab. 2011;96:3615-3627.
15
Perry WF, Hughes JF. The urinary excretion and thyroid uptake of iodine in renal disease. J Clin Invest. 1952;31:457-463.
16
Cho SJ, Suh CH, Baek JH, Chung SR, Choi YJ, Lee JH. Diagnostic performance of CT in detection of metastatic cervical lymph nodes in patients with thyroid cancer: a systematic review and meta-analysis. Eur Radiol. 2019;29:4635-4647.
17
Xing Z, Qiu Y, Yang Q, et al. Thyroid cancer neck lymph nodes metastasis: meta-analysis of US and CT diagnosis. Eur J Radiol. 2020;129:109103.
18
Kim R, Kim CK, Park JJ, et al. Prognostic significance for long-term outcomes following radical prostatectomy in men with prostate cancer: evaluation with prostate imaging reporting and data system version 2. Korean J Radiol. 2019;20:256-264.
19
Ozdemir D, Cuhaci FN, Ozdemir E, et al. The role of postoperative Tc-99m pertechnetate scintigraphy in estimation of remnant mass and prediction of successful ablation in patients with differentiated thyroid cancer. Nucl Med Commun. 2016;37:640-645.
20
Giovanella L, Paone G, Ruberto T, Ceriani L, Trimboli P. 99mTc-pertechnetate scintigraphy predicts successful postoperative ablation in differentiated thyroid carcinoma patients treated with low radioiodine activities. Endocrinol Metab (Seoul). 2019;34:63-69.
21
World Health Organization. Assessment of iodine deficiency disorders and monitoring their elimination: a guide for programme managers. 3rd ed. Geneva: World Health Organization; 2007. Available from: https://apps.who.int/iris/handle/10665/43781
22
Sohn SY, Choi JH, Kim NK, et al. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment. Thyroid. 2014;24:872-877.
23
Padovani RP, Kasamatsu TS, Nakabashi CC, et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy. Thyroid. 2012;22:926-930.
24
Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005;118:706-714.
25
Yonekura Y, Mattsson S, Flux G, et al. ICRP publication 140: radiological protection in therapy with radiopharmaceuticals. Ann ICRP. 2019;48:5-95.
26
International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides. Ann ICRP. 2004;34:v-vi, 1-79. Erratum in: Ann ICRP. 2004;34:281. Erratum in: Ann ICRP. 2006;36:77. Erratum in: Ann ICRP. 2013;42:341.
27
Fofi C, Festuccia F, Barberi S, et al. Hemodialysis in patients requiring 131I treatment for thyroid carcinoma. Int J Artif Organs. 2013;36:439-443.
28
Toubert ME, Michel C, Metivier F, Peker MC, Rain JD. Iodine-131 ablation therapy for a patient receiving peritoneal dialysis. Clin Nucl Med. 2001;26:302-305.
29
Kaptein EM, Levenson H, Siegel ME, Gadallah M, Akmal M. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clin Endocrinol Metab. 2000;85:3058-3064.
30
Pahlka RB, Sonnad JR. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model. Health Phys. 2006;91:227-237.
31
Pasqual E, Schonfeld S, Morton LM, et al. Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies. J Clin Oncol. 2022;40:1439-1449. Erratum in: J Clin Oncol. 2022;40:2283.
32
International Atomic Energy Agency. Radiation protection and safety in medical uses of ionizing radiation: specific safety guide. Vienna: International Atomic Energy Agency; 2018. Available from: https://www.iaea.org/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation
33
International Atomic Energy Agency. Quantitative nuclear medicine imaging: concepts, requirements and methods. Vienna: International Atomic Energy Agency; 2014. Available from: https://www.iaea.org/publications/10380/quantitative-nuclear-medicine-imaging-concepts-requirements-and-methods
